Market Overview:
The global mumps drug market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of mumps, rising demand for better treatment options, and growing awareness about mumps. The market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into RIT 4385, Schwarz vaccine strain (Wistar RA 27/3), and others. On the basis of application, the market is segmented into hospitals, clinics, and others.
Product Definition:
Mumps is a virus that can cause swelling of the salivary glands, fever, headache, and muscle aches. It is usually spread through saliva or mucus from the mouth, nose, or throat. Mumps drug is important in preventing mumps infection.
RIT 4385:
RIT 4385 is a prescription drug used to treat or prevent mumps. It is also marketed as Orgasia and Mumprex. Ritronipride, the active ingredient in RIT 4385, is an anti-epileptic drug which prevents the development of epilepsy in patients suffering from seizures due to epilepsy. Epilepsy can be treated with surgery (lesionectomy), medication (carbamazepine), or both depending on the type and degree of epilepsy.
Schwarz:
Schwarz is a German word which means Black. It is also used in the English language to refer to any dark-coloured medicine or drug. The origin of the name Schwarz comes from Latin and Greek roots, which both mean “Black”.
Application Insights:
Based on application, the global mumps drug market has been segmented into hospital, clinic and others. The hospital segment dominated the market in 2017 owing to increasing number of reported cases due to circulation of virus among multiple population groups. In addition, a rise in number of healthcare facilities along with growing awareness about disease transmission is expected to drive demand for drugs during 2018-2030 period.
The Clinic segment is anticipated to witness significant growth over the forecast period owing to rising awareness about immunization against measles and other viral infections among parents globally. Increasing travel & tourism activities are further likely fuel demand for these vaccines across various regions including Europe, Asia Pacific and Middle East & Africa during the same period which will subsequently boost industry growth over next few years.
Regional Analysis:
North America dominated the global market in 2017. The region is expected to maintain its position during the forecast period due to increasing cases of mumps and rising awareness about vaccination programs. In addition, growing healthcare infrastructure and high purchasing power are some other factors contributing toward regional growth.
Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to increasing healthcare expenditure, rising number of vaccines being developed, improving economic conditions & favorable regulatory framework & growing immunization initiatives by WHO and UNICEF coupled with government support for mass vaccination programs in countries such as India China Japan Malaysia Indonesia Thailand Philippines South Korea Pakistan Sri Lanka Bangladesh & Vietnam among others are expected to drive this market over the next eight years. Moreover, these countries have a large target population base which makes it an attractive destination for global players operating in this space as well as new entrants looking for a foothold in rapidly developing markets across Asia Pacific region & MEA & Latin America areas).
Growth Factors:
- Increasing incidence of mumps
- Growing awareness about the benefits of mumps vaccine
- Rising demand for mumps drugs in developing countries
- Technological advancements in the field of mumps drug development
- increasing funding for research and development on new vaccines
Scope Of The Report
Report Attributes
Report Details
Report Title
Mumps Drug Market Research Report
By Type
RIT 4385, Schwarz, Wistar RA 27/3, Others
By Application
Hospital, Clinic, Others
By Companies
Beijing Minhai Biotechnology Co., Ltd, Beijing Tiantan Biological Products Co., Ltd., China National Pharmaceutical Group Corporation, GlaxoSmithKline Plc, Organic Vaccines, Prometheon Pharma, LLC, Sinovac Biotech Ltd., Zydus Cadila Healthcare Limited
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
163
Number of Tables & Figures
115
Customization Available
Yes, the report can be customized as per your need.
Global Mumps Drug Market Report Segments:
The global Mumps Drug market is segmented on the basis of:
Types
RIT 4385, Schwarz, Wistar RA 27/3, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Beijing Minhai Biotechnology Co., Ltd
- Beijing Tiantan Biological Products Co., Ltd.
- China National Pharmaceutical Group Corporation
- GlaxoSmithKline Plc
- Organic Vaccines
- Prometheon Pharma, LLC
- Sinovac Biotech Ltd.
- Zydus Cadila Healthcare Limited
Highlights of The Mumps Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- RIT 4385
- Schwarz
- Wistar RA 27/3
- Others
- By Application:
- Hospital
- Clinic
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Mumps Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Mumps is a vaccine-preventable disease caused by the mumps virus. Symptoms of mumps include fever, headache, muscle aches, and swelling in the salivary glands. Mumps can lead to serious complications such as deafness or meningitis (a serious infection of the brain). Treatment for mumps typically includes rest and fluids, paracetamol for pain relief, and antibiotics if there is an infection.
Some of the major players in the mumps drug market are Beijing Minhai Biotechnology Co., Ltd, Beijing Tiantan Biological Products Co., Ltd., China National Pharmaceutical Group Corporation, GlaxoSmithKline Plc, Organic Vaccines, Prometheon Pharma, LLC, Sinovac Biotech Ltd., Zydus Cadila Healthcare Limited.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Mumps Drug Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Mumps Drug Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Mumps Drug Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Mumps Drug Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Mumps Drug Market Size & Forecast, 2020-2028
4.5.1 Mumps Drug Market Size and Y-o-Y Growth
4.5.2 Mumps Drug Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 RIT 4385
5.2.2 Schwarz
5.2.3 Wistar RA 27/3
5.2.4 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinic
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Mumps Drug Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Mumps Drug Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 RIT 4385
9.6.2 Schwarz
9.6.3 Wistar RA 27/3
9.6.4 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinic
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 RIT 4385
10.6.2 Schwarz
10.6.3 Wistar RA 27/3
10.6.4 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinic
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 RIT 4385
11.6.2 Schwarz
11.6.3 Wistar RA 27/3
11.6.4 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinic
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 RIT 4385
12.6.2 Schwarz
12.6.3 Wistar RA 27/3
12.6.4 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinic
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 RIT 4385
13.6.2 Schwarz
13.6.3 Wistar RA 27/3
13.6.4 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinic
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Mumps Drug Market: Competitive Dashboard
14.2 Global Mumps Drug Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Beijing Minhai Biotechnology Co., Ltd
14.3.2 Beijing Tiantan Biological Products Co., Ltd.
14.3.3 China National Pharmaceutical Group Corporation
14.3.4 GlaxoSmithKline Plc
14.3.5 Organic Vaccines
14.3.6 Prometheon Pharma, LLC
14.3.7 Sinovac Biotech Ltd.
14.3.8 Zydus Cadila Healthcare Limited
